Therapeutic advances in functional gastrointestinal disease: Irritable bowel syndrome

Therapeutic Advances in Gastroenterology

Volumn 2, Issue 3, 2009, Pages 169-181

  Gaman, Alexandru ^a   Bucur, Maria Cristina ^a   Kuo, Braden ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Drug therapy; Efficacy; Irritable bowel syndrome; Side effects

Indexed keywords

ALOSETRON; ANTIBIOTIC AGENT; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; CILANSETRON; CITALOPRAM; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CROFELEMER; ESCITALOPRAM; EZLOPITANT; GUANYLATE CYCLASE; MEN 10930; NAPADUTANT; NEUROTROPHIN; NOLPITANTIUM; OSANETANT; PRUCALOPRIDE; PUMOSETRAG; RAMOSETRON; RENZAPRIDE; SB 235375; SEROTONIN 3 AGONIST; SEROTONIN 3 ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; SOMATOSTATIN DERIVATIVE; SR 222200; SR 489968; TACHYKININ RECEPTOR ANTAGONIST; TAK 637; TEGASEROD; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABDOMINAL PAIN; ANGINA PECTORIS; CLINICAL TRIAL; CONSTIPATION; GASTROINTESTINAL DISEASE; HEART INFARCTION; HUMAN; INTESTINE MOTILITY; IRRITABLE COLON; ISCHEMIC COLITIS; NEUROIMAGING; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PHARMACOGENOMICS; PREVALENCE; PRIORITY JOURNAL; REVIEW; STROKE; UNSPECIFIED SIDE EFFECT;

EID: 77953374338     PISSN: 1756283X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1756283X08103656     Document Type: Review

References (101)

1. Andresen, V., Camilleri, M., Busciglio, I.A., Grudell, A., Burton, D., Mckinzie, S. et al. (2007) Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. Gastroenterology 133: 761-768.
2. Andrews, P.L. (1999) Cyclic vomiting syndrome: timing, targets, and treatment - a basic science perspective. Dig Dis Sci 44: 31S-38S.
3. Arnold, L.M., Pritchett, Y.L., D'Souza, D.N., Kajdasz, D.K., Iyengar, S. and Wernicke, J.F. (2007) Duloxetine for the treatment of fibromyalgia in women: pooled results from two randomized, placebo-controlled clinical trials. J Womens Health (Larchmt) 16: 1145-1156.
4. Awouters, F., Megens, A., Verlinden, M., Schuurkes, J., Niemegeers, C. and Janssen, P.A. (1993) Loperamide. Survey of studies on mechanism of its antidiarrheal activity. Dig Dis Sci 38: 977-995.
5. Banks, W.A., Schally, A.V., Barrera, C.M., Fasold, M.B., Durham, D.A., Csernus, V.J. et al. (1990) Permeability of the murine blood-brain barrier to some octapeptide analogs of somatostatin. Proc Natl Acad Sci U S A 87: 6762-6766.
6. Bertrand, P.P. and Galligan, J.J. (1995) Signal-transduction pathways causing slow synaptic excitation in guinea pig myenteric AH neurons. Am J Physiol 269: G710-G720
7. Budhoo, M.R., Harris, R.P. and Kellum, J.M. (1996) 5-hydroxytryptamine-induced Cl- transport is mediated by 5-HT3 and 5-HT4 receptors in the rat distal colon. Eur J Pharmacol 298: 137-144.
8. Camilleri, M., Chey, W.Y., Mayer, E.A., Northcutt, A.R., Heath, A., Dukes, G.E. et al. (2001) A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Intern Med 161: 1733-1740.
9. Camilleri, M., Northcutt, A.R., Kong, S., Dukes, G.E., Mcsorley, D. and Mangel, A.W. (2000) Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet 355: 1035-1040.
10. Chang, L., Ameen, V.Z., Dukes, G.E., Mcsorley, D.J., Carter, E.G. and Mayer, E.A. (2005) A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS. Am J Gastroenterol 100: 115-123.
11. Chang, L., Chey, W.D., Harris, L., Olden, K., Surawicz, C. and Schoenfeld, P. (2006) Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data. Am J Gastroenterol 101: 1069-1079.
12. Chey, W.Y., Jin, H.O., Lee, M.H., Sun, S.W. and Lee, K.Y. (2001) Colonic motility abnormality in patients with irritable bowel syndrome exhibiting abdominal pain and diarrhea. Am J Gastroenterol 96: 1499-1506.
13. Chial, H.J., Camilleri, M., Ferber, I., Delgado-Aros, S., Burton, D., McKinzie, S. et al. (2003) Effects of venlafaxine, buspirone, and placebo on colonic sensorimotor functions in healthy humans. Clin Gastroenterol Hepatol 1: 211-218.
14. Coates, M.D., Johnson, A.C., Greenwood-Van Meerveld, B. and Mawe, G.M. (2006) Effects of serotonin transporter inhibition on gastrointestinal motility and colonic sensitivity in the mouse. Neurogastroenterol Motil 18: 464-471.
15. Corleto, V.D., Romano, G., Severi, C., Annibale, B., Nasoni, S., Strom, R. et al. (1998) Human circular colonic smooth muscle cells possess active somatostatin receptors. Ital J Gastroenterol Hepatol 30: 505-509.
16. Corleto, V.D., Severi, C., Romano, G., Tattoli, I., Weber, H.C., Stridsberg, M. et al. (2006) Somatostatin receptor subtypes mediate contractility on human colonic smooth muscle cells. Neurogastroenterol Motil 18: 217-225.
17. Coulie, B., Szarka, L.A., Camilleri, M., Burton, D.D., McKinzie, S., Stambler, N. et al. (2000) Recombinant human neurotrophic factors accelerate colonic transit and relieve constipation in humans. Gastroenterology 119: 41-50.
18. Creed, F., Fernandes, L., Guthrie, E., Palmer, S., Ratcliffe, J., Read, N. et al. (2003) The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Gastroenterology 124: 303-317.
19. Creed, F., Tomenson, B., Guthrie, E., Ratcliffe, J., Fernandes, L., Read, N. et al. (2008) The relationship between somatisation and outcome in patients with severe irritable bowel syndrome. J Psychosom Res 64: 613-620.
20. Cuppoletti, J., Malinowska, D.H., Tewari, K.P., Li, Q.J., Sherry, A.M., Patchen, M.L. et al. (2004) SPI-0211 activates T 84 cell chloride transport and recombinant human CLC-2 chloride currents. Am J Physiol Cell Physiol 287: C1173-C1183
21. D'Amato, M.A.T. (1999) The efficacy and safety of the CCK-A receptor antagonist dexloxglumide in IBS. Gut 45: A258.
22. Dapoigny, M., Bellanger, J., Bonaz, B., Bruley Des Varannes, S., Bueno, L., Coffin, B. et al. (2004) Irritable bowel syndrome in France: a common, debilitating and costly disorder. Eur J Gastroenterol Hepatol 16: 995-1001.
23. de Maeyer, J.H., Lefebvre, R.A. and Schuurkes, J.A. (2008) 5-HT4 receptor agonists: similar but not the same. Neurogastroenterol Motil 20: 99-112.
24. Delafoy, L., Gelot, A., Ardid, D., Eschalier, A., Bertrand, C., Doherty, A.M. et al. (2006) Interactive involvement of brain derived neurotrophic factor, nerve growth factor, and calcitonin gene related peptide in colonic hypersensitivity in the rat. Gut 55: 940-945.
25. Delaney, C.P., Weese, J.L., Hyman, N.H., Bauer, J., Techner, L., Gabriel, K. et al. (2005) Phase III trial of alvimopan, a novel, peripherally acting, mu opioid antagonist, for postoperative ileus after major abdominal surgery, Dis Colon Rectum 48: 1114-1125; discussion 1125-1116; author reply 1127-1119.
26. Delvaux, M., Louvel, D., Lagier, E., Scherrer, B., Abitbol, J.L. and Frexinos, J. (1999) The kappa agonist fedotozine relieves hypersensitivity to colonic distention in patients with irritable bowel syndrome. Gastroenterology 116: 38-45.
27. Emery, P.T., Higgs, N.B., Warhurst, A.C., Carlson, G.L. and Warhurst, G. (2002) Anti-secretory properties of non-peptide somatostatin receptor agonists in isolated rat colon: luminal activity and possible interaction with P-glycoprotein. Br J Pharmacol 135: 1443-1448.
28. Emmanuel, A.V., Roy, A.J., Nicholls, T.J. and Kamm, M.A. (2002) Prucalopride, a systemic enterokinetic, for the treatment of constipation. Aliment Pharmacol Ther 16: 1347-1356.
29. Evans, B.W., Clark, W.K., Moore, D.J. and Whorwell, P.J. (2004) Tegaserod for the treatment of irritable bowel syndrome. Cochraine Databse Syst Rev 1: 1-55.
30. Eutamene, H., Theodorou, V., Fioramonti, J. and Bueno, L. (1997) Rectal distention-induced colonic net water secretion in rats involves tachykinins, capsaicin sensory, and vagus nerves. Gastroenterology 112: 1595-1602.
31. Evangelista, S. (2007) Drug evaluation: pumosetrag for the treatment of irritable bowel syndrome and gastroesophageal reflux disease. Curr Opin Investig Drugs 8: 416-422.
32. Fioramonti, J., Gaultier, E., Toulouse, M., Sanger, G.J. and Bueno, L. (2003) Intestinal antinociceptive behaviour of NK 3 receptor antagonism in conscious rats: evidence to support a peripheral mechanism of action. Neurogastroenterol Motil 15: 363-369.
33. Fujita, T., Yokota, S., Sawada, M., Majima, M., Ohtani, Y. and Kumagai, Y. (2005) Effect of MKC-733, a 5-HT receptor partial agonist, on bowel motility and symptoms in subjects with constipation: an exploratory study. J Clin Pharm Ther 30: 611-622.
34. Fukudo, S., Nomura, T. and Hongo, M. (1998) Impact of corticotropin-releasing hormone on gastrointestinal motility and adrenocorticotropic hormone in normal controls and patients with irritable bowel syndrome. Gut 42: 845-849.
35. George, A.M., Meyers, N.L. and Hickling, R.I. (2008) Clinical trial: renzapride therapy for constipation-predominant irritable bowel syndrome - multicentre, randomized, placebo-controlled, double-blind study in primary healthcare setting. Aliment Pharmacol Ther 27: 830-837.
36. Gershon, M.D. and Tack, J. (2007) The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology 132: 397-414.
37. Greenwood-Van Meerveld, B., Johnson, A.C., Cochrane, S., Schulkin, J. and Myers, D.A. (2005) Corticotropin-releasing factor 1 receptor-mediated mechanisms inhibit colonic hypersensitivity in rats. Neurogastroenterol Motil 17: 415-422.
38. Grider, J.R., Piland, B.E., Gulick, M.A. and Qiao, L.Y. (2006) Brain-derived neurotrophic factor augments peristalsis by augmenting 5-Ht and calcitonin gene-related peptide release. Gastroenterology 130: 771-780.
39. Guthrie, E., Creed, F., Fernandes, L., Ratcliffe, J., van der Jagt, J., Martin, J. et al. (2003) Cluster analysis of symptoms and health seeking behaviour differentiates subgroups of patients with severe irritable bowel syndrome. Gut 52: 1616-1622.
40. Halpert, A., Dalton, C.B., Diamant, N.E., Toner, B.B., Hu, Y., Morris, C.B. et al. (2005) Clinical response to tricyclic antidepressants in functional bowel disorders is not related to dosage. Am J Gastroenterol 100: 664-671.
41. Harasiuk, A., Klupinska, G., Walecka-Kapica, E., Forys, S., Felicka, E., Piotrowski, W. et al. (2007) [Secretion of serotonin and melatonin in patients with functional dyspepsia]. Pol Merkur Lekarski 22: 336-340.
42. Hasler, W.L., Soudah, H.C. and Owyang, C. (1993) A somatostatin analogue inhibits afferent pathways mediating perception of rectal distention. Gastroenterology 104: 1390-1397.
43. Hicks, G.A., Dehaven-Hudkins, D.L. and Camilleri, M. (2004) Opiates in the control of gastrointestinal tract function: current knowledge and new avenues for research. Neurogastroenterol Motil 16(Suppl. 2): 67-70.
44. Holzer, P. (2004) Opioids and opioid receptors in the enteric nervous system: from a problem in opioid analgesia to a possible new prokinetic therapy in humans. Neurosci Lett 361: 192-195.
45. Houghton, L.A., Cremonini, F., Camilleri, M., Busciglio, I., Fell, C., Cox, V. et al. (2007) Effect of the Nk (3) receptor antagonist, talnetant, on rectal sensory function and compliance in healthy humans. Neurogastroenterol Motil 19: 732-743.
46. Inadomi, J.M., Fennerty, M.B. and Bjorkman, D. (2003) Systematic review: the economic impact of irritable bowel syndrome. Aliment Pharmacol Ther 18: 671-682.
47. Johanson, J.F., Drossman, D.A., Panas, R., Wahle, A. and Ueno, R. (2008) Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation. Aliment Pharmacol Ther 27: 685-696.
48. Julia, V., Morteau, O. and Bueno, L. (1994) Involvement of neurokinin 1 and 2 receptors in viscerosensitive response to rectal distension in rats. Gastroenterology 107: 94-102.
49. Kall, E., Lindstrom, E. and Martinez, V. (2007) The serotonin reuptake inhibitor citalopram does not affect colonic sensitivity or compliance in rats. Eur J Pharmacol 570: 203-211.
50. Kamp, E.H., Beck, D.R. and Gebhart, G.F. (2001) Combinations of neurokinin receptor antagonists reduce visceral hyperalgesia. J Pharmacol Exp Ther 299: 105-113.
51. Kelleher, D., Johanson, J., Pobiner, B., Carter, E. and Dukes, G. (2006) Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist - a study in patients with chronic idiopathic constipation (CIC) not taking opioid medication. Am J Gastroenterol 101: s480.
52. Kindt, S. and Tack, J. (2007) Mechanisms of serotonergic agents for treatment of gastrointestinal motility and functional bowel disorders. Neurogastroenterol Motil 19(Suppl. 2): 32-39.
53. Kuiken, S.D., Tytgat, G.N. and Boeckxstaens, G.E. (2003) The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: a double blind, randomized, placebo-controlled study. Clin Gastroenterol Hepatol 1: 219-228.
54. Lecci, A., Capriati, A. and Maggi, C.A. (2004) Tachykinin NK 2 receptor antagonists for the treatment of irritable bowel syndrome. Br J Pharmacol 141: 1249-1263.
55. Lee, O.Y., Munakata, J., Naliboff, B.D., Chang, L. and Mayer, E.A. (2000) A double-blind parallel group pilot study of the effects of CJ-11974 and placebo on perceptual and emotional responses to recto-sigmoid distentions in IBS patients. Gastroenterology 118: A846.
56. Lembo, A., Johnston, J., MacDougall, J., Lavins, B., Fitch, D., Jeglinski, B. et al. (2008) Linaclotide significantly improved bowel habits and relieved abdominal symptoms in adults with chronic constipation: data from a large 4-week, randomized, double-blind, placebo-controlled study. Gastroenterology 135: 295.
57. Lembo, T., Plourde, V., Shui, Z., Fullerton, S., Mertz, H., Tache, Y. et al. (1996) Effects of the corticotropin-releasing factor (CRF) on rectal afferent nerves in humans. Neurogastroenterol Motil 8: 9-18.
58. Lembo, T., Wright, R.A., Bagby, B., Decker, C., Gordon, S., Jhingran, P. et al. (2001) Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 96: 2662-2670.
59. Lordal, M., Navalesi, G., Theodorsson, E., Maggi, C.A. and Hellstrom, P.M. (2001) A novel tachykinin NK 2 receptor antagonist prevents motility-stimulating effects of neurokinin a in small intestine. Br J Pharmacol 134: 215-223.
60. Martinez, V., Wang, L., Rivier, J., Grigoriadis, D. and Tache, Y. (2004) Central CRF, urocortins and stress increase colonic transit via CRF 1 receptors while activation of CRF 2 receptors delays gastric transit in mice. J Physiol 556: 221-234.
61. Mayer, E.A. and Bradesi, S. (2003) Alosetron and irritable bowel syndrome. Expert Opin Pharmacother 4: 2089-2098.
62. Mayer, E.A., Naliboff, B.D. and Chang, L. (2002) Evolving pathophysiological model of functional gastrointestinal disorders: implications for treatment. Eur J Surg (Suppl): 3-9.
63. McKeen, E.S., Feniuk, W. and Humphrey, P.P. (1994) Mediation by SRIF 1 receptors of the contractile action of somatostatin in rat isolated distal colon; studies using some novel SRIF analogues. Br J Pharmacol 113: 628-634.
64. Miranda, A., Peles, S., McLean, P.G. and Sengupta, J.N. (2006) Effects of the 5-HT3 receptor antagonist, alosetron, in a rat model of somatic and visceral hyperalgesia. Pain 126: 54-63.
65. Mule, F., D'Angelo, S., Tabacchi, G. and Serio, R. (2000) Involvement of tachykinin NK 2 receptors in the modulation of spontaneous motility in rat proximal colon. Neurogastroenterol Motil 12: 459-466.
66. Muller-Lissner, S.A., Bollani, S., Brummer, R.J., Coremans, G., Dapoigny, M., Marshall, J.K. et al. (2001) Epidemiological aspects of irritable bowel syndrome in Europe and North America. Digestion 64: 200-204.
67. Nagakura, Y., Kamato, T., Nishida, A., Ito, H., Yamano, M. and Miyata, K. (1996) Characterization of 5-hydroxytryptamine (5-HT) receptor subtypes influencing colonic motility in conscious dogs. Naunyn Schmiedebergs Arch Pharmacol 353: 489-498.
68. Nakai, A., Diksic, M., Kumakura, Y., D'Souza, D. and Kersey, K. (2005) The effects of the 5-HT3 antagonist, alosetron, on brain serotonin synthesis in patients with irritable bowel syndrome. Neurogastroenterol Motil 17: 212-221.
69. Okano, S., Ikeura, Y. and Inatomi, N. (2002) Effects of tachykinin NK 1 receptor antagonists on the viscerosensory response caused by colorectal distention in rabbits. J Pharmacol Exp Ther 300: 925-931.
70. Okano, S., Nagaya, H., Ikeura, Y., Natsugari, H. and Inatomi, N. (2001) Effects of Tak-637, a novel neurokinin-1 receptor antagonist, on colonic function in vivo. J Pharmacol Exp Ther 298: 559-564.
71. Onori, L., Aggio, A., Taddei, G., Ciccocioppo, R., Severi, C., Carnicelli, V. et al. (2001) Contribution of Nk 3 tachykinin receptors to propulsion in the rabbit isolated distal colon. Neurogastroenterol Motil 13: 211-219.
72. Onori, L., Aggio, A., Taddei, G., Loreto, M.F., Ciccocioppo, R., Vicini, R. et al. (2003) Peristalsis regulation by tachykinin Nk 1 receptors in the rabbit isolated distal colon. Am J Physiol Gastrointest Liver Physiol 285: G325-G331
73. Parkman, H.P., Rao, S.S., Reynolds, J.C., Schiller, L.R., Wald, A., Miner, P.B. et al. (2003) Neurotrophin-3 improves functional constipation. Am J Gastroenterol 98: 1338-1347.
74. Paterson, W.G., Ford, D., Ganguli, S.C., Reynolds, R.P., Pliamm, L., O'Mahony, M. et al. (2008 a) A novel, oral 5HT3 partial agonist, DDP733, improves overall response in patients with irritable bowel syndrome and constipation (IBS-C): a randomized, double blind, placebo-controlled, parallel-group, dose-ranging. Gasteroenterology 134: A546-A547.
75. Paterson, W.G., Springer, J., O'Mahony, M., Reynolds, R.P., Ganguli, S.C., Feagan, B. et al. (2008 b) A randomized, double-blind, placebo-controlled trial with a novel dual noradrenergic reuptake inhibitor (NARI) and 5-HT3 antagonist: results of a phase II 8-week study in female patients with diarrhea predominant irritable bowel syndrome (D-IBS). Gasteroenterology 134: A-50.
76. Pimentel, M., Chatterjee, S., Chow, E.J., Park, S. and Kong, Y. (2006 a) Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: subanalysis of a double-blind randomized controlled study. Dig Dis Sci 51: 1297-1301.
77. Pimentel, M., Park, S., Mirocha, J., Kane, S.V. and Kong, Y. (2006 b) The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med 145: 557-563.
78. Prins, N.H., Akkermans, L.M., Lefebvre, R.A. and Schuurkes, J.A. (2000) 5-HT (4) receptors on cholinergic nerves involved in contractility of canine and human large intestine longitudinal muscle. Br J Pharmacol 131: 927-932.
79. Renzi, D., Pellegrini, B., Tonelli, F., Surrenti, C. and Calabro, A. (2000) Substance P (neurokinin-1) and neurokinin a (neurokinin-2) receptor gene and protein expression in the healthy and inflamed human intestine. Am J Pathol 157: 1511-1522.
80. Roka, R., Rosztoczy, A., Leveque, M., Izbeki, F., Nagy, F., Molnar, T. et al. (2007) A pilot study of fecal serine-protease activity: a pathophysiologic factor in diarrhea-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol 5: 550-555.
81. Romano, S., Judge, R., Dillon, J., Shuler, C. and Sundell, K. (1999) The role of fluoxetine in the treatment of premenstrual dysphoric disorder. Clin Ther 21: 615-633, discussion 613.
82. Sanger, G.J. and Wardle, K.A. (1994) Constipation evoked by 5-HT3-receptor antagonism: evidence for heterogeneous efficacy among different antagonists in guinea-pigs. J Pharm Pharmacol 46: 666-670.
83. Sharara, A.I., Aoun, E., Abdul-Baki, H., Mounzer, R., Sidani, S. and Elhajj, I. (2006) A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol 101: 326-333.
84. Shu, X.Q. and Mendell, L.M. (1999) Neurotrophins and hyperalgesia. Proc Natl Acad Sci U S A 96: 7693-7696.
85. Spiller, R. (2007) Recent advances in understanding the role of serotonin in gastrointestinal motility in functional bowel disorders: alterations in 5-HT signalling and metabolism in human disease. Neurogastroenterol Motil 19(Suppl. 2): 25-31.
86. Stanghellini, V., de Ponti, F., de Giorgio, R., Barbara, G., Tosetti, C. and Corinaldesi, R. (2003) New developments in the treatment of functional dyspepsia. Drugs 63: 869-892.
87. Tache, Y., Martinez, V., Wang, L. and Million, M. (2004) CRF 1 receptor signaling pathways are involved in stress-related alterations of colonic function and viscerosensitivity: implications for irritable bowel syndrome. Br J Pharmacol 141: 1321-1330.
88. Tack, J., Broekaert, D., Corsetti, M., Fischler, B. and Janssens, J. (2006) Influence of acute serotonin reuptake inhibition on colonic sensorimotor function in man. Aliment Pharmacol Ther 23: 265-274.
89. Talley, N.J. (2003) Evaluation of drug treatment in irritable bowel syndrome. Br J Clin Pharmacol 56: 362-369.
90. Talley, N.J., Kellow, J.E., Boyce, P., Tennant, C., Huskic, S. and Jones, M. (2008) Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial. Dig Dis Sci 53: 108-115.
91. Tayama, J., Sagami, Y., Shimada, Y., Hongo, M. and Fukudo, S. (2007) Effect of alpha-helical CRH on quantitative electroencephalogram in patients with irritable bowel syndrome. Neurogastroenterol Motil 19: 471-483.
92. Toulouse, M., Coelho, A.M., Fioramonti, J., Lecci, A., Maggi, C. and Bueno, L. (2000) Role of tachykinin Nk 2 receptors in normal and altered rectal sensitivity in rats. Br J Pharmacol 129: 193-199.
93. Tuo, B.G., Sellers, Z., Paulus, P., Barrett, K.E. and Isenberg, J.I. (2004) 5-HT induces duodenal mucosal bicarbonate secretion via cAMP- and Ca2+-dependent signaling pathways and 5-HT4 receptors in mice. Am J Physiol Gastrointest Liver Physiol 286: G444-G451.
94. Vale, W., Spiess, J., Rivier, C. and Rivier, J. (1981) Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science 213: 1394-1397.
95. Vassallo, M.J., Camilleri, M., Phillips, S.F., Steadman, C.J., Talley, N.J., Hanson, R.B. et al. (1992) Colonic tone and motility in patients with irritable bowel syndrome. Mayo Clin Proc 67: 725-731.
96. Venkova, K. and Greenwood-Van Meerveld, B. (2004) Effects of TAK-637 on Nk (1) receptor-mediated mechanisms regulating colonic secretion. Toxicol Appl Pharmacol 196: 215-222.
97. Viscusi, E.R., Goldstein, S., Witkowski, T., Andonakakis, A., Jan, R., Gabriel, K. et al. (2006) Alvimopan, a peripherally acting mu-opioid receptor antagonist, compared with placebo in postoperative ileus after major abdominal surgery: results of a randomized, double-blind, controlled study. Surg Endosc 20: 64-70.
98. Walsh, J.H. (1994) Gastrointestinal Hormones: Physiology of the Gastrointestinal Tract., 3rd edition. New York : Raven Press.
99. Wang, H., Zhang, Y.Q., Ding, Y.Q. and Zhang, J.S. (2002) Localization of neurokinin B receptor in mouse gastrointestinal tract. World J Gastroenterol 8: 172-175.
100. Wassem, R., McDonald, M. and Racine, J. (2002) Fibromyalgia: patient perspectives on symptoms, symptom management, and provider utilization. Clin Nurse Spec 16: 24-28 discussion 29-30.
101. Wood, J.D. and Galligan, J.J. (2004) Function of opioids in the enteric nervous system. Neurogastroenterol Motil 16(Suppl. 2): 17-28.